CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, marking a -3.5% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.3% for the day. Elsewhere, the Dow lost 0.48%, while the tech-heavy Nasdaq added 0.03%. Heading into today, shares of the company had lost 5.14% over the past month, lagging the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. The company is expected to report EPS of -$1.31, down 29.7% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.47 million, up 1311.83% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$6.57 per share and a revenue of $36.16 million, indicating changes of -51.38% and -3.11%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 93, this industry ranks in the top 38% of all industries, numbering over 250. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks